Developer of first-in-class targeted small molecule therapies designed to provide treatment for solid tumors. The company's therapies are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors and uses proprietary technology platform to rationally design protein-protein interaction inhibitors, enabling patient to begin treatment more quickly and result in a higher likelihood of a successful treatment.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC (Series A) | 26-Jun-2018 | $11.2M | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
2. Seed Round | 14-Dec-2015 | 00.000 | 00.000 | Completed | Product Development | |
1. Seed Round | 30-Apr-2014 | $226K | $226K | 00.000 | Completed | Generating Revenue |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 000,000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | ||
Seed | 00,000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | ||
Seed | 277,776 | $7.98 | $7.98 | 1x | $7.98 | 20.84% | ||
Ordinary | 25,000 | $9.34 | $9.34 | 1x | $9.34 | 1.88% |
Name | Representing | Role | Since |
---|---|---|---|
Anker Lundemose Ph.D | Self | Board Member | 000 0000 |
Emmanuelle Coutanceau Ph.D | Novo Holdings | Board Member | 000 0000 |
Jasper Bos Ph.D | M Ventures | Board Member | 000 0000 |
Keno Gutierrez Ph.D | M Ventures | Board Member | 000 0000 |
Klaus Schollmeier Ph.D | Self | Chairman | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Aglaia Management B.V. | Venture Capital | Minority | 000 0000 | 000000 0 | |
Eva Capital | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
M Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Novo Holdings | Venture Capital | Minority | 000 0000 | 000000 0 |